Compare NIO Inc. (NIO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Sana Biotechnology Inc — how do they compare? NIO Inc. trades at $3.58 (market cap $8.62B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: NIO Inc. is far larger — about 10.3× Sana Biotechnology Inc's market cap, and NIO Inc. is more actively traded (39,648,517 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Sana Biotechnology Inc for 23 Days on average.
| NIO | SANA | |
|---|---|---|
Market Cap | $8.62B | $836.71M |
Volume | 39,648,517 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $5.92 |
52-Week Low | $3.37 | $2.68 |
Typical Hold Time | 81 Days | 23 Days |
Enterprise Value | $6.52B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 3.67% today and near its 52-week low, reflecting bearish technical signals. The company reported Q3 2026 deliveries up 25.4% but continues to post net losses, with a -4.17% net income margin in 2026. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38 billion for NIO Power, aiming to expand charging infrastructure amid a competitive EV price war in China.
The outlook remains challenging due to persistent losses and high debt, though revenue growth and analyst consensus suggest long-term potential. Risks include intense competition, margin pressure, and macroeconomic headwinds. With a $6.23 average price target, analysts see 83% upside, but investors must weigh profitability improvements against ongoing cash burn.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
